A review of 2,500+ studies finds medical cannabis has proven benefits for only a few conditions, while many popular claims lack strong evidence. The analysis also highlights notable risks, underscoring the need for cautious, evidence based guidance.
A comprehensive new review from UCLA Health is challenging some of the most common assumptions about medical cannabis. Despite its rising popularity for conditions like chronic pain, anxiety and insomnia, researchers say the scientific proof simply isn’t as strong as public belief suggests. After evaluating more than 2,500 studies published over the last 15 years, the team concluded that cannabis has well-established medical value for only a limited set of conditions and far more uncertainty than many realise.
Where the Evidence Falls Short
Lead researcher Dr. Michael Hsu notes that enthusiasm for cannabis has surged, driven in part by personal testimonials and growing commercial interest. Yet when the team examined high-quality clinical trials, guidelines and meta-analyses, they found that most commonly cited benefits lacked solid backing.
The strongest support exists only for FDA-approved cannabinoid medications, primarily used for HIV/AIDS-related appetite loss, chemotherapy induced nausea and vomiting, and rare but severe childhood seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome. For widespread issues like chronic pain, the evidence remains mixed, and current guidelines still do not recommend cannabis as a first-line option.
Related Articles
The Hidden Risks Users Should Know
The review also highlights safety concerns that often receive less public attention. Long-term studies show that adolescents using high-potency cannabis face greater risks of psychotic symptoms and anxiety disorders. Even among adults, daily or high dose use was linked to increased chances of cannabis use disorder and heightened cardiovascular risks including heart attack and stroke compared with occasional use.
About 29% of medical cannabis users met criteria for cannabis use disorder, underscoring the need for clinicians to screen carefully before recommending THC-containing products.
Bridging the Gap With Better Guidance
The authors urge clinicians to take an evidence-based approach when discussing cannabis with patients, weighing potential harms alongside any benefits. They also call for more rigorous scientific research to fill current gaps, noting that many studies are observational and may not reflect real-world patient diversity or today’s increasingly potent products.
While medical cannabis isn’t without value, this review makes one message clear: patients deserve realistic expectations grounded in science—not marketing, hype or hopeful assumptions.
